Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Pfizer is gearing up for a major push into the obesity drug market, drawing parallels to its success with Viagra. Despite ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

Pfizer has agreed to acquire weight-loss drugmaker Metsera in a transaction that could exceed $10 billion. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront, along with a ...

The Delaware Chancery Court denied Pfizer Inc.’s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating the existing merger agreement in favor of ...